Advertisement
Journal Home
Search for

Volume 41, Issue 6, Pages 419-427 (December 2009)


View previous. 7 of 24 View next.

CD40 Ligand Deficiency: Neurologic Sequelae With Radiographic Correlation

Shrinivas Bishu, MDCorresponding Author Informationemail address, Deepak Madhavan, MD, Phillip Perez, MD, Lucy Civitello, MD§, Shuying Liu, RN, Margaret Fessler, RN, Steven M. Holland, MD, Ashish Jain, MD, Maryland Pao, MD#

Received 19 March 2009; accepted 6 July 2009.

Patients with CD40 ligand deficiency are susceptible to central nervous system infections, but to date the neurologic progression or long-term outcome of central nervous system complications have not been reported in detail. Characterizing the central nervous system complications of immune deficiencies can lead to the identification of new pathogens. For this study, clinical data were reviewed on patients with both CD40 ligand deficiency and neurodegeneration, identified from a larger cohort of 31 patients. Five patients had progressive neurologic and cognitive decline in the absence of clinical signs of acute fulminant encephalitis, with anatomic brain abnormalities and high mortality (60%). Despite multiple evaluations, no pathogens were identified in four patients, all of whom were on standard intravenous immunoglobulin therapy at illness presentation. This clinical phenotype of progressive decline without acute fulminant encephalitis is similar to chronic enteroviral encephalitis in X-linked agammaglobulinemia, another condition with severe humoral immune defects. Whether infection secondary to subtherapeutic levels of central nervous system immunoglobulin G (IgG), inadequately protective levels of serum IgG, or impaired CD40 ligand-dependent IgG-independent antiviral responses contributed remains undetermined. Emerging gene-chip techniques applied in patients with primary immune deficiencies may identify heretofore unknown viruses. Prospective neurocognitive and evaluation of patients with CD40 ligand deficiency may identify affected patients before overt clinical signs appear.

 Section on Neuroadaptation and Protein Metabolism, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland

 Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, Nebraska

 Department of Psychiatry, Georgetown University, Washington, DC

§ Department of Neurology, Children's National Medical Center, Washington, DC

 Laboratory of Host Defenses, National Institute of Allergy and Infectious Disease, Bethesda, Maryland

 Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Disease, Bethesda, Maryland

# Psychiatry Consultation Liaison Service, Office of the Clinical Director, National Institute of Mental Health, Bethesda, Maryland

Corresponding Author InformationCommunications should be addressed to: Dr. Bishu; Section on Neuroadaptation and Protein Metabolism; NIMH-NIH; 9000 Rockville Pike; Building 10, Room 2D54; Bethesda, MD 20892-1298.

PII: S0887-8994(09)00349-X

doi:10.1016/j.pediatrneurol.2009.07.003


View previous. 7 of 24 View next.

Advertisement